SG10202111394XA - Combinatorial cancer immunotherapy - Google Patents

Combinatorial cancer immunotherapy

Info

Publication number
SG10202111394XA
SG10202111394XA SG10202111394XA SG10202111394XA SG10202111394XA SG 10202111394X A SG10202111394X A SG 10202111394XA SG 10202111394X A SG10202111394X A SG 10202111394XA SG 10202111394X A SG10202111394X A SG 10202111394XA SG 10202111394X A SG10202111394X A SG 10202111394XA
Authority
SG
Singapore
Prior art keywords
cancer immunotherapy
combinatorial cancer
combinatorial
immunotherapy
cancer
Prior art date
Application number
SG10202111394XA
Other languages
English (en)
Inventor
Timothy Kuan-Ta Lu
Russell Morrison Gordley
Tzu-Chiao Lin
Brian Scott Garrison
Philip Janmin Lee
Alba Gonzalez-Junca
Don-Hong Wang
Original Assignee
Senti Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senti Biosciences Inc filed Critical Senti Biosciences Inc
Publication of SG10202111394XA publication Critical patent/SG10202111394XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4635—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10202111394XA 2017-04-13 2018-04-13 Combinatorial cancer immunotherapy SG10202111394XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762485295P 2017-04-13 2017-04-13
US201762583343P 2017-11-08 2017-11-08

Publications (1)

Publication Number Publication Date
SG10202111394XA true SG10202111394XA (en) 2021-12-30

Family

ID=62092349

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10202111394XA SG10202111394XA (en) 2017-04-13 2018-04-13 Combinatorial cancer immunotherapy

Country Status (10)

Country Link
US (2) US11446332B2 (pt)
EP (2) EP4317422A3 (pt)
JP (2) JP2020516654A (pt)
KR (1) KR20190141695A (pt)
CN (2) CN117838729A (pt)
AU (1) AU2018251898A1 (pt)
CA (1) CA3059634A1 (pt)
IL (1) IL269810A (pt)
SG (1) SG10202111394XA (pt)
WO (1) WO2018191619A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7305300B2 (ja) * 2014-11-05 2023-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 併用免疫療法
AU2018251898A1 (en) 2017-04-13 2019-10-31 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
KR20240067973A (ko) 2018-07-11 2024-05-17 액팀 테라퓨틱스, 인코퍼레이티드 조작된 면역자극성 박테리아 균주 및 이의 용도
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
KR20210094534A (ko) 2018-10-17 2021-07-29 센티 바이오사이언시스, 인코포레이티드 병용 암 면역 요법
EP3870600A1 (en) 2018-10-24 2021-09-01 Obsidian Therapeutics, Inc. Er tunable protein regulation
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
CN117468267A (zh) 2019-04-04 2024-01-30 艾可产品公益公司 提供耐油脂和耐水性质的纸浆组合物制造的模制品
US20220280609A1 (en) * 2019-07-17 2022-09-08 The Regents Of The University Of California Combination cancer therapy agents and methods
US20220378822A1 (en) * 2019-08-28 2022-12-01 Senti Bioscience, Inc. Combinatorial cancer immunotherapy
WO2021055731A1 (en) * 2019-09-20 2021-03-25 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Il-36 cytokine expressing oncolytic viruses for treating cancer
WO2021097144A2 (en) * 2019-11-12 2021-05-20 Actym Therapeutics, Inc. Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
CN112980886B (zh) * 2019-12-02 2022-02-22 河北森朗生物科技有限公司 一种能高效制备且应用安全的嵌合抗原受体t细胞及其制备方法与应用
EP4183872A4 (en) * 2020-07-16 2024-05-01 Shanghai Jiaotong University METHOD FOR IMMUNOTHERAPY BY TARGETED DELIVERY OF CHEMOKINES AND CYTOKINES BY A MESENCHYMAL STEM CELL
CN115433734A (zh) * 2022-06-01 2022-12-06 北京奇糖科技有限公司 核酸片段及其在制备肿瘤疫苗中的应用

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5714585A (en) 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
US5328988A (en) 1987-10-26 1994-07-12 Immunex Corporation Interleukin-7
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5674486A (en) 1991-06-25 1997-10-07 San Diego Regional Cancer Center Cancer immunotherapy with carrier cells
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
WO1994000484A1 (en) 1992-06-22 1994-01-06 Young Henry E Scar inhibitory factor and use thereof
US7534867B1 (en) 1993-05-19 2009-05-19 Schering Corporation Purified mammalian Flt3 ligands; agonists; antagonists
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
CZ307995A3 (en) 1993-05-24 1996-10-16 Immunex Corp Ligands for flt3 receptors
US5536657A (en) 1993-07-19 1996-07-16 Hoffmann-La Roche Inc. Recombinant DNA encoding human receptor for interleukin-12
US5591625A (en) 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
WO1995027722A1 (en) 1994-04-06 1995-10-19 Immunex Corporation Interleukin-15
US5780268A (en) 1995-12-06 1998-07-14 Incyte Pharmaceuticals Chemokine expressed in a mixed lymphocyte reaction
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
AU729579B2 (en) 1996-10-23 2001-02-01 Trustees Of The University Of Pennsylvania, The Immunotherapy and improved vaccines
US6187307B1 (en) 1997-01-31 2001-02-13 Research Corporation Technologies, Inc. Cancer immunotherapy with semi-allogeneic cells
US8034332B2 (en) * 1997-04-30 2011-10-11 Conkwest, Inc. Interleukin-secreting natural killer cell lines and methods of use
US6153182A (en) 1997-12-19 2000-11-28 Uab Research Foundation Lymphotactin as an adjuvant
WO1999061617A1 (en) 1998-05-29 1999-12-02 Human Genome Sciences, Inc. Interleukins-21 and 22
US20010023070A1 (en) 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
DE19833476B4 (de) 1998-07-24 2005-08-25 Huss, Ralf, Dr. Genetisch modifizierte CD34-Negative, adhärent wachsende hämatopoetische Stammzellen und deren Verwendung in der Gentherapie
US6392126B1 (en) 1999-02-25 2002-05-21 Pioneer Hi-Bred International, Inc. Adenosine deaminase homologues and uses thereof
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US6929932B2 (en) 2001-11-05 2005-08-16 Zymogenetics, Inc. IL-21 antagonists
AU2003213666A1 (en) 2002-03-02 2003-09-16 Board Of Regents, The University Of Texas System Local production and/or delivery of anti-cancer agents by stromal cell precursors
US20050063947A1 (en) 2002-03-27 2005-03-24 Patrick Hwu Method for treating cancer in humans
US20040033217A1 (en) 2002-05-31 2004-02-19 Padmavathy Vanguri Intraperitoneal delivery of genetically engineered mesenchymal stem cells
WO2004042023A2 (en) * 2002-11-01 2004-05-21 Five Prime Therapeutics, Inc. Stem cell libraries
JP5148873B2 (ja) 2003-06-27 2013-02-20 エチコン、インコーポレイテッド 臍帯組織由来の分娩後細胞、及びその作成及び使用方法
KR101130220B1 (ko) 2003-06-27 2012-04-13 엔씨 메디컬 리서치 가부시키가이샤 간엽계 세포를 유효 성분으로 하는 뇌신경 질환 치료용 체내 투여용 약제
US7052772B2 (en) 2003-08-14 2006-05-30 3M Innovative Properties Company Material for packaging electronic components
US20050037306A1 (en) 2003-08-16 2005-02-17 Tetsuo Nakatsu Candle system for enhancing burning and improving volatiles performance and a manufacturing method for the same
WO2005037306A1 (en) 2003-10-17 2005-04-28 Novo Nordisk A/S Combination therapy
WO2005037218A2 (en) 2003-10-17 2005-04-28 Actis Biologics, Inc. Lentiviral vector delivery of il-21 for treatment of cancer
GB0400031D0 (en) 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
EP1778298A4 (en) 2004-04-01 2010-03-31 Univ Pennsylvania LIPOPROTEIN-NANO PLATFORMS
CA3052445C (en) * 2004-07-10 2023-08-22 Kerry S. Campbell Genetically modified human natural killer cell lines
KR101443473B1 (ko) 2004-07-22 2014-09-22 에라스무스 유니버시티 메디컬 센터 로테르담 Ｖh 결합 영역의 분리 방법
DE102005057426A1 (de) 2005-11-30 2007-05-31 Andritz Küsters GmbH & Co. KG Unterdruck-Bandfördervorrichtung zum Führen einer laufenden Bahn
NZ596494A (en) 2006-01-13 2013-07-26 Us Gov Nat Inst Health Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
CA2636867C (en) 2006-01-13 2015-12-01 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics using codon optimized il-15 and methods for using the same
US7833754B2 (en) 2006-01-13 2010-11-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services IL-12 for expression in mammalian cell
KR100788930B1 (ko) 2006-04-18 2007-12-27 포항공과대학교 산학협력단 항암 조성물
WO2007149493A2 (en) 2006-06-22 2007-12-27 Immugen Inc Restoration of hearing loss
US7993918B2 (en) 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
US8304931B2 (en) 2006-12-18 2012-11-06 Decicon, Inc. Configurable power supply integrated circuit
EP3357338A1 (en) * 2007-03-30 2018-08-08 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
DK2147116T3 (en) 2007-04-20 2016-05-30 Sigma Tau Rare Disease Ltd STABLE RECOMBINANT adenosine deaminase
SI2147122T1 (sl) 2007-04-20 2015-01-30 Sigma-Tau Pharma Limited Encimatska terapija proti raku
US20110038836A1 (en) * 2007-04-23 2011-02-17 The Board Of Regents, The University Of Texas System Device and Method for Transfecting Cells for Therapeutic Use
ES2654303T3 (es) 2007-05-04 2018-02-13 University Health Network Inmunoterapia de IL-12 contra el cáncer
EP2229948B1 (en) 2007-05-24 2012-12-19 Apceth GmbH & Co. KG Mesenchymal CD34- stem cells for use in diabetes gene therapy
EP2034025A1 (en) 2007-09-04 2009-03-11 Freie Universität Berlin Inflammation-induced anti-inflammatory gene expression
US20110020242A1 (en) 2007-12-12 2011-01-27 Gang Zheng High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles
KR101619341B1 (ko) 2008-01-28 2016-05-11 (주)아모레퍼시픽 바닐로이드 수용체 길항체로서의 신규 화합물, 이의 이성질체 또는 약제학적으로 허용가능한 염, 및 이를 함유하는 약학 조성물
MX340972B (es) 2008-10-08 2016-08-02 Intrexon Corp Celulas manipuladas por ingenieria que expresan multiples inmunomoduladores, y uso de las mismas.
RU2562154C2 (ru) 2008-11-19 2015-09-10 Антродженезис Корпорейшн Амниотические адгезивные клетки
CA2758120C (en) 2009-04-13 2014-08-19 Apceth Gmbh & Co. Kg Engineered mesenchymal stem cells and method of using same to treat tumors
CN102804664B (zh) 2009-05-08 2015-05-06 日本电气株式会社 通信系统、通信设备、通信方法和程序
WO2011114919A1 (en) 2010-03-19 2011-09-22 Semiconductor Energy Laboratory Co., Ltd. Semiconductor device
US9487800B2 (en) 2010-09-08 2016-11-08 Chemotherapeutisches Forschunginstitut Georg-Speyer-Haus Interleukin 15 as selectable marker for gene transfer in lymphocytes
WO2012051210A2 (en) 2010-10-11 2012-04-19 The Administrators Of The Tulane Educational Fund Mesenchymal stem cells and related therapies
CN107164330A (zh) 2011-04-08 2017-09-15 贝勒医学院 使用嵌合细胞因子受体逆转肿瘤微环境的影响
EP2755487B1 (en) 2011-09-16 2018-12-19 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
CA2876512C (en) 2012-07-11 2022-12-13 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
CA2876499C (en) 2012-07-12 2021-10-26 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
EP3011055B1 (en) 2013-06-19 2019-08-28 University Of Miami Classification system, methods and kit for classifying breast cancer
EP3021853A1 (en) * 2013-07-18 2016-05-25 Baylor College Of Medicine Method of enhancing potency of immune cells
JP2015030819A (ja) 2013-08-05 2015-02-16 株式会社ジェイテクト アクリルゴム組成物およびこれを備えたシール装置
WO2015035235A1 (en) 2013-09-06 2015-03-12 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) Compositions and methods for increasing mesenchymal stromal cell migration to tumors
JP2017507935A (ja) 2014-02-11 2017-03-23 アントフロゲネシス コーポレーション マイクロオルガノイド、並びにその製造方法及び使用方法
US10155024B2 (en) 2014-03-28 2018-12-18 The Catholic University Of Korea Industry-Academic Cooperation Foundation Composition for preventing or treating B-cell lymphoma comprising IL-21 expressing mesenchymal stem cells
JP6468712B2 (ja) 2014-03-28 2019-02-13 大和ハウス工業株式会社 通信ユニット
KR20160011916A (ko) 2014-07-23 2016-02-02 삼성전자주식회사 얼굴 인식을 통한 사용자 식별 방법 및 장치
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
AU2015300966A1 (en) 2014-08-08 2017-02-16 Janssen Pharmaceutica Nv Bruton's tyrosine kinase inhibitor combinations and uses thereof
US9918718B2 (en) 2014-08-08 2018-03-20 DePuy Synthes Products, Inc. Embolic coil delivery system with retractable mechanical release mechanism
AU2015306231B2 (en) * 2014-08-18 2019-11-21 Apceth Gmbh & Co. Kg Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
WO2016103071A1 (en) 2014-12-23 2016-06-30 Husqvarna Ab Lawn monitoring and maintenance via a robotic vehicle
KR20160089688A (ko) 2015-01-20 2016-07-28 삼성전자주식회사 엑스선 영상 장치, 및 그 제어방법
US20160237407A1 (en) 2015-02-17 2016-08-18 Batu Biologics, Inc. Universal donor chimeric antigen receptor cells
WO2016146819A1 (en) 2015-03-18 2016-09-22 Apceth Gmbh & Co. Kg Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells
US10874724B2 (en) 2015-05-22 2020-12-29 University Of Houston System Enzymatic immunomodulation of solid tumors and uses thereof
KR20240013282A (ko) * 2015-06-10 2024-01-30 이뮤너티바이오, 인크. 암을 치료하기 위한 변형된 nk-92 세포
CN107809960B (zh) 2015-06-30 2020-11-20 史密夫和内修有限公司 具有螺纹插塞的缝线锚定器系统
EP3317399B1 (en) * 2015-06-30 2024-06-26 Cellectis Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
US11075843B2 (en) 2015-06-30 2021-07-27 British Telecommunications Public Limited Company Model management in a dynamic QOS environment
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
SG10201913151TA (en) * 2015-09-09 2020-03-30 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Genetic engineering of macrophages for immunotherapy
CN105206757B (zh) 2015-11-05 2016-09-07 京东方科技集团股份有限公司 有机发光二极管及其制作方法、显示基板和显示装置
US10008344B2 (en) 2015-11-11 2018-06-26 Htc Corporation Switch assembly and hand-held device
US10533157B1 (en) * 2015-12-03 2020-01-14 Nantbio, Inc. Recombinant NK cells expressing co-stimulatory molecules
WO2017133175A1 (en) 2016-02-04 2017-08-10 Nanjing Legend Biotech Co., Ltd. Engineered mammalian cells for cancer therapy
US20210205370A1 (en) 2016-02-18 2021-07-08 Pluristem Ltd. Methods and compositions for treating cancers and neoplasms
KR101833971B1 (ko) 2016-02-19 2018-03-02 사회복지법인 삼성생명공익재단 중간엽 줄기세포 또는 xcl1을 포함하는 근육질환의 예방 또는 치료용 약학적 조성물
US11434294B2 (en) 2016-02-25 2022-09-06 Cell Medica, Inc. Binding members to PD-L1
AU2017277499B2 (en) 2016-06-07 2022-07-28 The Pacific Heart, lung & Blood Institute Compositions and methods for treating cancer
CA3029197A1 (en) 2016-06-24 2017-12-28 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars), compositions and methods thereof
SG11201811432WA (en) 2016-08-19 2019-03-28 Curevac Ag Rna for cancer therapy
US11529393B2 (en) 2016-10-10 2022-12-20 The Board Of Trustees Of The Leland Stanford Junior University Mesenchymal stem cells expressing anti-inflammatory cytokines and methods of use
JP6607179B2 (ja) 2016-12-15 2019-11-20 トヨタ自動車株式会社 車両の制御装置
WO2018161026A1 (en) 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Il15 compositions and methods for immunotherapy
WO2018161038A1 (en) 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Il12 compositions and methods for immunotherapy
EP3589373A4 (en) 2017-03-03 2020-12-23 Obsidian Therapeutics, Inc. COMPOSITIONS AND PROCEDURES FOR IMMUNOTHERAPY
US20200085876A1 (en) 2017-03-17 2020-03-19 Senti Biosciences, Inc. Immunomodulating cell circuits
AU2018251898A1 (en) 2017-04-13 2019-10-31 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
WO2018213731A1 (en) 2017-05-18 2018-11-22 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
KR20210094534A (ko) 2018-10-17 2021-07-29 센티 바이오사이언시스, 인코포레이티드 병용 암 면역 요법
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
CN111849905B (zh) * 2019-04-18 2023-03-24 上海交通大学 间充质干细胞靶向运输趋化因子和细胞因子的免疫疗法
US20220378822A1 (en) * 2019-08-28 2022-12-01 Senti Bioscience, Inc. Combinatorial cancer immunotherapy

Also Published As

Publication number Publication date
EP4317422A2 (en) 2024-02-07
US20200206271A1 (en) 2020-07-02
US20230270789A1 (en) 2023-08-31
CN110996975A (zh) 2020-04-10
CN117838729A (zh) 2024-04-09
JP2020516654A (ja) 2020-06-11
EP3610000A1 (en) 2020-02-19
AU2018251898A1 (en) 2019-10-31
US11446332B2 (en) 2022-09-20
CA3059634A1 (en) 2018-10-18
KR20190141695A (ko) 2019-12-24
WO2018191619A1 (en) 2018-10-18
IL269810A (en) 2019-11-28
JP2022180471A (ja) 2022-12-06
EP4317422A3 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
IL282080A (en) Combinatorial immunotherapy for cancer
IL269810A (en) Combined immunotherapy of cancer
ZA202005298B (en) Combination tumor immunotherapy
IL269405A (en) Anti-SIRP-alpha antibodies
IL268517A (en) Anti-tigit antibodies
IL268620A (en) Antibodies against LAG3
GB201709808D0 (en) Antibodies
HUE059237T2 (hu) GARP-TGF-béta antitestek
IL255390A (en) Antenna reflector
EP3292140A4 (en) Cancer immunotherapeutic
HK1257177A1 (zh) 腫瘤免疫治療
GB201720970D0 (en) Antibodies
GB201705065D0 (en) Hopper assembly
IL259786A (en) Conformal antenna
IL271067A (en) Anti-trkb antibodies
GB201800733D0 (en) Cancer
GB201720477D0 (en) Antenna
EP3247792A4 (en) Cancer immunotherapy
GB201814487D0 (en) Cancer
EP3618856A4 (en) MULTIPLE INDICATION MRNA CANCER IMMUNOTHERAPY
GB201703907D0 (en) Novel therapies for cancer
GB2565910B (en) Spiral antenna system
PL3752507T3 (pl) Synteza triazolochinozalinonów
GB201711785D0 (en) Antibodies
GB2546773B (en) Cancer